New Pancreatic Cancer Pill Shows 90% Disease Control Rate

For the first time, researchers have found a drug that works against the genetic mutations driving 90% of pancreatic cancers.

Daraxonrasib, a daily pill, just completed its first human trial with results that have doctors calling it one of the most important breakthroughs in solid tumor treatment. The Dana-Farber Cancer Institute tested the drug in 168 patients with advanced pancreatic cancer who had already undergone at least one round of chemotherapy.

At the optimal dose, 30% of patients saw their tumors respond positively. Even more remarkable: about 90% experienced disease control, meaning their cancer either shrank or stopped growing.

The drug works by blocking multiple cancer signals linked to RAS gene mutations. These mutations fuel tumor growth in more than 90% of pancreatic cancer cases, but older drugs only targeted rare RAS types uncommon in this cancer.

Lead researcher Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research, said the development could transform care. "If supported by future clinical trials, daraxonrasib would be a targeted therapy relevant to nearly all patients with advanced pancreatic cancer," he shared in a statement.

The trial participants did experience side effects, including rash, mouth inflammation, nausea, and diarrhea. Most patients managed these issues with supportive care, and very few had to stop treatment because of them.

Dr. Brian Slomovitz from Mount Sinai Medical Center, who wasn't involved in the study, called the results unprecedented. "Doubling the survival time in pretreated patients is unprecedented," he said, noting this could "reshape the treatment landscape" and establish a new standard of care.

Why This Inspires

Pancreatic cancer has long been one of the hardest cancers to treat, with few effective options available. This breakthrough matters because it targets the genetic root of the disease in nearly all patients, not just a small subset.

The drug is now moving to larger phase 3 trials to confirm whether it outperforms standard chemotherapy. While it's not yet a cure and still needs more research, the momentum is real.

For families facing this challenging diagnosis, daraxonrasib represents something they haven't had much of before: genuine hope backed by solid science.